A new SLAS Technology review article by researchers at the University of Southern California and the University of California, Los Angeles, sheds light on the growing number and more sophisticated designs of theranostic nanoparticles.
SLAS is pleased to announce the addition of Emilio Diez Monedero, Peter Brian Simpson and Severine Tamas-Lhoustau to the Society's Board of Directors. They begin three-year terms in February 2018.
A new SLAS Discovery article available for free ahead-of-print enables researchers to derive more clinically-relevant information from 3D cell culture models.
Discovering new drugs has never been easy and some potential drug targets have historically been viewed as too challenging and thus off limits for prosecution. In a new SLAS Discovery review, authors John S. Lazo et al. of the University of Virginia reflect on the nature of protein tyrosine phosphatases and explores reasons why these enzymes have been eschewed by drug hunters, and how the landscape is beginning to change.
A new report shows how microsystems can be used to understand processes in heart tissue in detail and to test newly developed compounds applied in the treatment of cardiac diseases.
An exploration of the latest understanding of the complex mechanisms behind OA pain offers new possibilities and potential treatment targets for osteoarthritis (OA) pain. New areas of research discussed include the use of combination therapies and the development of biomarkers to target effective pain treatment.
The August 2017 issue of SLAS Technology (formerly the Journal of Laboratory Automation) showcases 10 new reviews and original research reports that illustrate how the progression of research assays from qualitative outputs toward increasingly sensitive quantitative outputs is transforming life sciences and biomedical research and diagnostics by improving the ability of researchers and clinicians to detect and quantify increasingly complex assays.
Information generated by screening tools, readily available therapies and potential pathways to drug development are the cornerstone of informed clinical research and clinical trial design. In a new review in the August 2017 issue of SLAS Discovery (formerly the Journal of Biomolecular Screening), authors Eric Chevet, Ph.D., of Inserm U1242 (Rennes, France) et al. analyze the recent literature and review the impact of unfolded protein response (UPR) in health and disease.